Valvular heart disease associated with benfluorex therapy: Results from the French multicentre registry

European Journal of Echocardiography

Volumn 12, Issue 4, 2011, Pages 265-271

  Le Ven, Florent ^a   Tribouilloy, Christophe ^b   Habib, Gilbert ^c   Gueffet, Jean Pierre ^d   Marchaux, Sylvestre ^e   Eicher, Jean Christophe ^f   Blanchard Lemoine, Bndicte ^g   Rousseau, Juliette ^h   Hnon, Pierre ^b   Jobic, Yannick ^a   Etienne, Yves ^a  

^a BREST UNIVERSITY HOSPITAL   (France)

^b AMIENS UNIVERSITY HOSPITAL   (France)

^c University Hospital of Marseille   (France)

^d NANTES UNIVERSITY HOSPITAL   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f DIJON UNIVERSITY HOSPITAL   (France)

^g BICHAT HOSPITAL   (France)

^h CENTRE CARDIOLOGIQUE DU NORD   (France)

Author keywords

Drug induced valvular disease; Fibrotic valvular disease

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; BENFLUOREX; BROMOCRIPTINE; CABERGOLINE; DEXFENFLURAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOT ALKALOID; FENFLURAMINE; PHENTERMINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AORTA VALVE REGURGITATION; ARTICLE; BODY MASS; CLINICAL ARTICLE; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MITRAL VALVE REGURGITATION; MITRAL VALVE REPLACEMENT; MITRAL VALVE STENOSIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY VALVE INSUFFICIENCY; TREATMENT DURATION; TREATMENT OUTCOME; TRICUSPID VALVE REGURGITATION;

APPETITE DEPRESSANTS; BODY MASS INDEX; COMORBIDITY; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; FEMALE; FENFLURAMINE; FRANCE; HEART VALVE DISEASES; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; OBESITY; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 79953906808     PISSN: 15252167     EISSN: 15322114     Source Type: Journal    
DOI: 10.1093/ejechocard/jeq172     Document Type: Article

References (26)

1. Abenhaim L, Moride Y, Brenot F, Rich S, Benichok J, Kurz X et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;335:609-6.
2. Gardin JM, Schumacher D, Constantine G, Davis KD, Leung C, Reid CL Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA 2000;283:1703-9. (Pubitemid 30196210)
3. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-8. (Pubitemid 27360757)
4. Dahl CF, Allen MR, Urie PM, Hopkins PN. Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals. BMC Med 2008;6:34.
5. Moulin P, Andre M, Alawi H, dos Santos LC, Khalid AK, Koev D et al. Efficacy of benfluorex in combination with sulfonylurea in type 2 diabetic patients: an 18-week, randomized, double-blind study. Diabetes Care 2006;29:515-20. (Pubitemid 44115346)
6. Noize P, Sauer M, Bruneval P, Moreau M, Pathak A, Bagheri H et al. Valvular heart disease in a patient taking benfluorex. Fundam Clin Pharmacol 2006;20:577-8. (Pubitemid 44762174)
7. Boutet K, Frachon I, Jobic Y, Gut-Gobert C, Leroyer C, Carlhant-Kowalski D et al. Fenfluramine-like cardiovascular side-effects of benfluorex. Eur Respir J 2009;33: 684-8.
8. Rafel Ribera J, Casañas Muñoz R, Anguera Ferrando N, Batalla Sahún N, Castro Cels A, Pujadas Capmany R. Valvular heart disease associated with benfluorex. Rev Esp Cardiol 2003;56:215-6. (Pubitemid 36305071)
9. Gueffet J, Piriou N, Trochu J. Valvular heart disease associated with benfluorex. Arch Cardiovasc Dis 2010;103:342-3.
10. Tribouilloy C, Rusinaru D, Henon P, Tribouilloy L, Leleu F, Andréjak M et al. Restrictive organic mitral regurgitation associated with benfluorex therapy. Eur J Echocardiogr 2010;11:614-21.
11. Frachon I, Etienne Y, Jobic Y, Le Gal G, Humbert M, Leroyer C Benfluorex and unexplained valvular heart disease: a case-control study. PLoS ONE 2010;5: e10128.
12. Lancellotti P, Tribouilloy C, Hagendorff A, Moura L, Popescu BA, Agricola E et al. European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 1: aortic and pulmonary regurgitation (native valve disease). Eur J Echocardiogr 2010;11:223-44.
13. Lancellotti P, Moura L, Pierard LA, Agricola E, Popescu BA, Tribouilloy C et al. European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 2: mitral and tricuspid regurgitation (native valve disease). Eur J Echocardiogr 2010;11:307-32.
14. Baumgartner H, Hung J, Bermejo J, Chambers JB, Evangelista A, Griffin BP et al. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. Eur J Echocardiogr 2009;10:1-25.
15. FSSAPS. Suspension d'autorisation de mise sur le marché des médicaments contenat du benfluorex-communiqué. Available at http://www.afssaps.fr/Infos-de-securite/communiques-de-presse/ suspension-d-autorisation-de-mise-sur-le-marche-des-medicaments-contenant-du- benfluorex-communique (accessed 7 December 2009).
16. European Medicines Agency Press Office. European Medicines Agency rec-ommends withdrawal of benfluorex from the market in European Union. EMA/CHMP/815033/2009. 18 December 2009. www.ema.europa.eu/docs/en-GB/document- library/Press-release/2010/01/WC500059714.pdf
17. Bhattacharyya S, Schapira AH, Mikhailidis DP, Davar J. Drug-induced fibrotic valvular heart disease. Lancet 2009;374:577-85.
18. Roth BL Drugs and valvular heart disease. N Engl J Med 2007;356:6-9.
19. Zolkowska D, Baumann MH, Rothman RB. Chronic fenfluramine administration increases plasma serotonin (5-hydroxytryptamine) to nontoxic levels. J Pharmacol Exp Ther 2008;324:791-7. (Pubitemid 351185838)
20. Rothman RB, Redmon JB, Raatz SK, Kwong CA, Swanson JE, Bantle JP. Chronic treatment with phentermine combined with fenfluramine lowers plasma seroto-nin. Am J Cardiol 2000;85:913-5, A10. (Pubitemid 30157868)
21. Jagroop IA, Mikhailidis DP. An investigation of the serotonergic effects of fenflur-amine, dexfenfluramine and dexnorfenfluramine using platelets as neuronal models. Platelets 2000;11:161-5. (Pubitemid 30345423)
22. Droogmans S, Kerkhove D, Cosyns B, Van Camp G. Role of echocardiography in toxic heart valvulopathy. Eur J Echocardiogr 2009;10:467-76.
23. Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ et al. Evi-dence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000; 102:2836-41.
24. European Comission. European Comission Decision of 14.6.2010 concerning, in the framework of Article 107 of Directive 2001/83/EC of the European Parlia-ment and of the Council, the marketing authorisations for medicinal products for human use which contain the active substance "benfluorex" . Available at www.ec.europa.eu/health/documents.
25. Weissman NJ, Tighe JF, Gottdiener JS, Gwynne JT. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfen-fluramine, or placebo. Sustained-Release Dexfenfluramine Study Group. N Engl J Med 1998;339:725-32. (Pubitemid 28417355)
26. Burger AJ, Sherman HB, Charlamb MJ, Kim J, Asinas LA, Flickner SR et al. Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months. J Am Coll Cardiol 1999;34: 1153-8. (Pubitemid 29500553)